Thromb Haemost 1984; 51(02): 266-268
DOI: 10.1055/s-0038-1661073
Original Article
Schattauer GmbH Stuttgart

Histidine-Rich Glycoprotein Modulates the Anticoagulant Activity of Heparin in Human Plasma

H R Lijnen
The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
,
B Van Hoef
The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
,
D Collen
The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 09. Januar 1984

Accepted 22. Februar 1984

Publikationsdatum:
19. Juli 2018 (online)

Summary

Addition of 0.05 IU of heparin per ml normal plasma prolongs its thrombin time from 20 to 27s, but that of plasma specifically depleted in histidine-rich glycoprotein (by immunoadsorption) from 20 to 180s. Reconstitution of the depleted plasma with normal plasma or with purified histidine-rich glycoprotein normalizes its thrombin time.

In 54 plasma samples from hospitalized patients a significant negative correlation was found between the anticoagulant activity of heparin measured by thrombin inhibition and the plasma level of histidine-rich glycoprotein (r = 0.69). It is concluded that the level of histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma to an extent which appears to be pharmacologically and possibly clinically relevant.

 
  • References

  • 1 Höök M, Björk I, Hopwood J, Lindahl U. Separation of high-activity and low-activity heparin-species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976; 66: 90-93
  • 2 Läm LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
  • 3 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
  • 4 Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma J Biol Chem 1983; 258: 3803-3808
  • 5 Lijnen HR, Rylatt DB, Collen D. Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor. Biochim Biophys Acta 1983; 742: 109-115
  • 6 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
  • 7 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983 (in press)
  • 8 Jordan R, Beeler D, Rosenberg R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-2913
  • 9 Olson ST, Shore JD. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement. J Biol Chem 1981; 256: 11065-11072
  • 10 Lijnen HR, Jacobs G, Collen D. Histidine-rich glycoprotein in a normal and a clinical population. Thromb Res 1981; 22: 519-523
  • 11 Lijnen HR, Van HoefB, Collen D. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III. Thromb Res 1983; 50: 560-562